anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Facial paralysis can be a consequence of traumatic facial nerve injury, iatrogenic causes, malignancy, congenital syndromes, and viral infections. Prolonged paralysis can result in ocular complications, articulation difficulties, impaired feeding, and difficulty in conveying emotion through expressive movement. The current treatment for permanent facial paralysis is facial reanimation surgery, which encompasses a broad range of procedures that restore form and function to the paralyzed face.

The importance of understanding the health utility of facial paralysis and the value of facial reanimation surgery increases. PEG-fusion is a promising therapy for patients that have or will have nerve conditions or injuries resulting in facial palsy that can be addressed surgically. Patients that have clinical evidence of facial paralysis requiring facial nerve repair from conditions or interventions that have or may result in paralysis will be evaluated for participation. The primary objective is to assess the safety of NTX-001 across 12 months following the nerve repair. The study will measure improvement in Facial Grading System (FG) for efficacy. Additionally, measures will include an EMG evaluation for assessment of nerve function intraoperatively, image-based automatic facial landmark analysis, improvement in Facial Clinimetric Evaluation Scale score, and Patient Global Impression of Change Response (PGIC).
This pilot project is a randomised control trial with 24 participants. Diets will consist of 1200 and 1500kcals for females and males, respectively. The control arm is to receive the Ministry of Health guidelines percentage energy from carbohydrate (50-55%), protein (10-15%) and fat (30%). The intervention arm is to be lower in carbohydrate (40%), higher in protein (30%), moderate fat (30%). Participants will be required to continue the diet for at least 8 weeks while waiting for surgery. At baseline and at eight weeks their weight, hip circumference, waist circumference, neck circumference and body composition measurements will be taken. During their prescribed diet they are required to fill out a 3-day diet record. At the end of eight weeks the participants will perform a twenty-four hour urine collect for urea and creatinine. This will help determine adherence. Post-surgery (21-28 days) they will be required to complete a surgical recovery questionnaire and the above measurements will be recorded again. These data will be collected over a period beginning January 2015. It is expected that the intervention arm will have greater weight loss and better preservation of muscle mass leading to a better surgical recovery score. However because the intervention requires a higher intake of protein this may have an effect on adherence and acceptability in these participants. There are no known adverse effects of the intervention diet in the short term.
The invention provides a medicinal liquor for treating deafness. The medicinal liquor provided by the invention is composed of the following ingredients of: by weight, 40 parts of xanthium, 40 parts of Radix Saposhnikoviae, 45 parts of Radix Astragali, 20 parts of chinaroot greenbrier rhizome, 25 parts of arctium fruit, 50 parts of Negundo Chastetree Fruit, 10 parts of ginseng, 15 parts of Chinese cassia tree, 25 parts of akebia stem and 1000 parts of liquor. A manufacturing method of the medicinal liquor comprises the following steps of: crushing xanthium, Radix Saposhnikoviae, Radix Astragali, chinaroot greenbrier rhizome, arctium fruit, rehmanniae radix, Negundo Chastetree Fruit, ginseng, Chinese cassia tree and akebia stem, putting into a cloth bag, putting into a container, adding liquor, immersing for 7 days and filtering to remove slag. The invention aims to provide the medicinal liquor for treating deafness. The medicinal liquor has an obvious effect of treating the deafness symptom. The manufacturing method of the medicinal liquor is simple.
The invention relates to an IAPP (Islet Amyloid Polypeptide) analog injection with better stability. The preparation consists of pramlintide acetate, antiseptic, isoosmotic adjustment agent. pH value adjusting agent, antioxidant, local painkiller and solvent, wherein the antioxidant is added to enhance the stability of the preparation and the local painkiller is added to mitigate the pain of patient without impacting basic remedy. The preparation process of the preparation mainly comprises weighing, dissolution, pyrogen adsorption by activated carbon, filtration, end filtration, subpackage and piston injection and capping. The preparation is used as a medicine for the auxiliary treatment of Type I and Type II diabetes in order to achieve the therapeutic effect of assisting in blood sugar reduction. The preparation is stable in quality, accurate in therapeutic effect and favorable for being accepted by patients.
The program "young In Favor of Myself" will be delivered to adolescence aged 10-12, over 3 months. The program contains nine weekly, 90-min sessions that focus on Media literacy, self-esteem, self-image and body image. The parents won't participate in the program, they will get only a brochure about Media literacy, self-esteem, self-image and body image. All participants will complete a self-report questionnaire at baseline, after the program ends, and three months after the completion of the program.
BACKGROUND: Toxoplasma gondii (T. gondii) and Helicobacter pylori (H. pylori) are among the most prevalent foodborne parasitic and bacterial infections worldwide. However, the concurrent impact of coinfection on gastric pathology has yet to be studied in depth. The effect of coinfection generally either adds a synergetic or antagonistic impact; we aimed in the current work to assess the impact of T. gondii coinfection on the progression of H. pylori-associated gastric pathology and reporting H. pylori virulent strains. The study was conducted on 82 patients complaining of persistent gastrointestinal symptoms with failed treatment response and prone to endoscopy. They were subjected to stool examination to detect H. pylori antigen, serological screening for latent toxoplasmosis, endoscopy, histopathological examination, and molecular detection of H. pylori virulence strains in gastric biopsies. Out of the 82 patients, 62 patients were positive for H. pylori antigen in stool and 55 patients confirmed positivity by histopathology; out of them, 37 patients had isolated Vac As1 variants, 11 patients had combined Vac As1 and Cag A variants, and 7 patients had combined Vac As1, Cag A and VacAs2 variants. Patients with the combined two or three variances showed significantly deteriorated histopathological features than patients with a single Vac As1 variant (P < 0.05). Latent toxoplasmosis was positive among 35/82 patients. Combined H. pylori and Toxoplasma gondii infection had significantly marked inflammation than patients with isolated infection (P < 0.05).
CONCLUSION: Screening for toxoplasmosis among H. pylori-infected patients is recommended as it is considered a potential risk factor for gastric inflammation severity. H. pylori gastric inflammation may be heightened by Toxoplasma coinfection.
The present invention provides methods for inhibiting bone loss comprising administering to a mammal in need of treatment a bone loss inhibiting amount of a compound of formula I or formula II       I wherein R1 is -H or is a bivalent moiety which distances L from the B-ring by 6-8 intervening atoms;   R2 is -H or selected from the group consisting of hydrogen, a straight or branched, saturated or unsaturated chain having 1-5 carbon atoms, a substituted or unsubstituted cycloalkyl group having 5-7 carbon atoms, a bivalent moiety which joins R3 and L to form a 5- to 7-membered heterocyclic ring, and halo-substituted derivatives of the foregoing;          R3 is absent or selected from the group consisting of hydrogen, a straight or branched, saturated or unsaturated chain having 1-5 carbon atoms, a substituted or unsubstituted bivalent moiety which joins R2 and L to form a 5- to 7-membered heterocyclic ring, and halo-substituted derivatives of the foregoing;          R4 is hydrogen or lower alkyl; R5 and R6 each are independently hydrogen, hydroxy, or a moiety which is converted to hydroxy in vivo;          L is -CON< or -N<; and the dotted line in the B-ring is an optional bond; or a pharmaceutically acceptable salt thereof; and   II wherein Q is a moiety having the formula   ; or ? R1 ? B ? R7 ? L ? G ;           R1 is absent or is a bivalent moiety which distances L from the B-ring by 6-8 intervening atoms;          R2 is absent or selected from the group consisting of hydrogen, a straight or branched, saturated or unsaturated chain having 1-5 carbon atoms, a substituted or unsubstituted cycloalkyl group having 5-7 carbon atoms, a bivalent moiety which joins R3 and L to form a 5- to 7-membered heterocyclic ring, and halo-substituted derivatives of the foregoing;          R3 is absent or selected from the group consisting of hydrogen, a straight or branched, saturated or unsaturated chain having 1-5 carbon atoms, a substituted or unsubstituted bivalent moiety which joins R2 and L to form a 5- to 7-membered heterocyclic ring, and halo-substituted derivatives of the foregoing;         L is -CON< or -N<; B is -O-, -S-, -CH2-phenyl-O-, -phenyl-O-, or -benzyl -O -;           R7 is absent or selected from the group consisting of straight- or branched-chain alkylene, straight- or branched-chain alkenylene, phenylene, and fluoro-substituted analogs of the foregoing;     G is a moiety which together with L forms a substituted or unsubstituted heterocyclic ring having at least one nitrogen atom or is selected from the group consisting of hydrogen, lower alkyl, lower alkenyl, lower alkynyl,  (C3-C7)cycloalkyl, halo(lower)alkyl, cyano(lower)alkyl, carboxy(lower)alkyl, (lower)alkoxycarbonyl(lower)alkyl,  (C6-C10)aryl,  (C7-C11)aryl akyl, di(lower)alkylamino(lower)alkyl, and fluoro-substituted analogs of the foregoing;          R4 is hydrogen or lower alkyl; R5 and R6 each are independently hydrogen, hydroxy, or a moiety which is converted to hydroxy in vivo;   Z is -O-, -S-, -CH2-, -NH-; or -N(CH3)-; and the dotted line in the B-ring is an optional bond; or a pharmaceutically acceptable salt thereof.
The present invention illustrates a method, non-transitory computer readable medium, and surgical computing device for improving surgical planning using machine learning. With this technique, a machine learning model is trained based on historical case log data sets associated with patients who have undergone a surgical procedure. The machine learning model is applied to current patient data for a current patient to generate a prediction equation. The current patient data includes anatomical data of an anatomical structure of the current patient. The predictive equations are optimized to generate the size, position and orientation of the implant, and the resection required to achieve the position and orientation of the implant relative to the current patient's anatomy as part of the current patient's surgical plan. The machine learning model is updated based on the current patient data and the current results.
Major Depressive Disorder — It is generally agreed that acute episodes of major depression require several months or longer of sustained pharmacologic therapy. Maintenance of efficacy in MDD was demonstrated with Cymbalta as monotherapy. Cymbalta should be administered at a total dose of 60 mg once daily. Patients should be periodically reassessed to determine the need for maintenance treatment and the appropriate dose for such treatment [see Clinical Studies (14.1)].

Generalized Anxiety Disorder — It is generally agreed that episodes of generalized anxiety disorder require several months or longer of sustained pharmacological therapy. Maintenance of efficacy in GAD was demonstrated with Cymbalta as monotherapy. Cymbalta should be administered in a dose range of 60-120 mg once daily. Patients should be periodically reassessed to determine the continued need for maintenance treatment and the appropriate dose for such treatment [see Clinical Studies (14.2)].

Diabetic Peripheral Neuropathic Pain — As the progression of diabetic peripheral neuropathy is highly variable and management of pain is empirical, the effectiveness of Cymbalta must be assessed individually. Efficacy beyond 12 weeks has not been systematically studied in placebo-controlled trials.

Fibromyalgia — Fibromyalgia is recognized as a chronic condition. The efficacy of Cymbalta in the management of fibromyalgia has been demonstrated in placebo-controlled studies up to 3 months. The efficacy of Cymbalta was not demonstrated in longer studies; however, continued treatment should be based on individual patient response.
PURPOSE: Suboptimal communication with clinicians, fragmented care and failure to align with patients' preferences are determinants of post intensive care unit (ICU) burden in family members. Our aim was to evaluate the impact of a nurse facilitator on family psychological burden.
METHODS: We carried out a randomised controlled trial in five ICUs in France comparing standard communication by ICU clinicians to additional communication and support by nurse facilitators. We included patients > 18 years, with expected ICU length of stay > 2 days, chronic life-limiting illness, and their family members. Facilitators were trained to help families to secure care in line with patient's goals, beginning in ICU and continuing for 3 months. Assessments were made at baseline and 1, 3 and 6 months post-randomisation. Primary outcome was the evolution of family symptoms of depression over 6 months using a linear mixed effects model on the depression subscale of the Hospital Anxiety and Depression Scale (HADS). Secondary outcomes included HADS-Anxiety, Impact of Event Scale-6, goal-concordant care and experience of serious illness (QUAL-E).
RESULTS: 385 patients and family members were enrolled. Follow-up at 1-, 3- and 6-month was completed by 284 (74%), 264 (68.6%) and 260 (67.5%) family members respectively. The intervention was associated with significantly more formal meetings between the ICU team and the family (1 [1-3] vs 2 [1-4]; p < 0.001). There was no significant difference between the intervention and control groups in evolution of symptoms of depression over 6 months (p = 0.91), nor in symptoms of depression at 6 months [0.53 95% CI (- 0.48; 1.55)]. There were no significant differences in secondary outcomes.
CONCLUSION: This study does not support the use of facilitators for family members of ICU patients.
Based on the characteristics of Kummell's disease (KD) and related anatomical structures of the thoracolumbar spine, a novel bone cement screw system has been designed to effectively avoid the cement loosening and displacement. This experiment aimed to assess the biological effects of the novel bone cement screw system in KD on fresh cadaveric thoracolumbar spine specimens, thereby discussing its potential application value and providing a foundation for clinical implementation. This study employed a total of 50 fresh female adult cadaver specimens. Each specimen underwent extraction of the T12 to L2 segment followed by the creation of an artificial KD model at the L1 segment and subsequent establishment of five distinct types of bone cement repair models. Model A represents the percutaneous vertebroplasty (PVP) model, Model B combines PVP with unilateral percutaneous pediculoplasty (PPP), Model C combines PVP with bilateral PPP, Model D introduces the novel bone cement screw combined with unilateral PVP, and Model E combines the novel screw with bilateral PVP, each group consists of 10 specimens. Subsequently, the six-axis spine robot was employed to execute cement three-dimensional biomechanical strength tests in six directions, including anterior flexion and posterior extension, left and right lateral bending, as well as left and right rotation. The novel bone cement screw, whether used unilaterally or bilaterally in combination with the PVP model, exhibits significantly reduced bone cement mobility and superior biomechanical stability during anterior flexion, posterior extension, left lateral bending, and right lateral bending (P<0.05).No significant differences were observed among the five models under both left and right rotation (P > 0.05).When comparing the novel bone cement screw combined with PVP unilaterally and bilaterally, no statistically significant difference was observed in the stability of bone cement across all six directions of motion (P>0.05). To conclude, this novel bone cement bridging screw system exhibits superior biomechanical stability compared to commonly used treatments. Furthermore, both unilateral and bilateral implementations of the novel bone cement screw system yield without significant differences observed. These findings present a reliable and innovative approach for clinical management of KD.
An excellent antipruritic drug which functions by a new mechanism. Also provided is a quinazoline derivative represented by the following general formula (1) or a salt thereof: (1) wherein R1 represents hydrogen or alkyl;  ring Q represents cyclohexylene or phenylene; A1 and A2 each represents a single bond or alkylene; E represents -NHCO-, etc.; A3 represents a single bond, a divalent (un)saturated aliphatic hydrocarbon group, etc.; R3 represents a noncyclic aliphatic hydrocarbon group, etc.; and R4 and R5 are the same or different and each represents hydrogen, alkyl, etc. The antipruritic drug contains as an active ingredient the derivative or a pharmaceutically acceptable salt of the derivative.
For all patients, the dose to the PTV will be kept constant at 60 Gy in 30 fractions at 2.0 Gy per fraction, SIBV will be kept constant at 72 Gy in 30 fractions at 2.4 Gy per fraction. Fractions given once a day, 5 times a week for six weeks. All patients will receive standard concurrent chemotherapy.
Vitamins are substances that our bodies need to develop and function normally. They include vitamins A, C, D, E, and K, choline, and the B vitamins (thiamin, riboflavin, niacin, pantothenic acid, biotin, vitamin B6, vitamin B12, and folate/folic acid). Vitamins are essential nutrients that enable your body to work properly and to stay healthy. Most vitamins can be found in the food that we eat or from vitamin supplements.
PURPOSE:To obtain the title substance obtained as an acid insoluble fraction containing lignin of phenolic high polymer compound extracted from a wooden material as a main ingredient and capable of adding to food in relatively large amounts without impairing characteristics of food. CONSTITUTION:The aimed substance obtained as an acid insoluble fraction containing lignin of phenolic high polymer compound extracted from a wooden material as a main ingredient. Furthermore, albumen and/or pellicle of cacao bean is directly used as the raw material or a material obtained by subjecting the albumen and/or pellicle to physical treatment such as pulverizing, chemical treatment such as various solvent extraction, biological treatment such as fermentation is used as a raw material and 40-98% concentrated sulfuric acid is added to the above-mentioned raw material at an amount of 2-10 times by vol. to hydrolyze the raw material and the hydrolyzate is filtered and cleaned to provide the aimed substance as the residue. The aimed substance has preferably physicochemical characteristics such as >=200 molecular weight, <=1% sugar content, 1.5-5. 5% nitrogen amount, <=10% fat content, <=10% ash and 5-40% methoxy group number.
Pemetrexed for injection is a folate analog metabolic inhibitor. The drug substance, pemetrexed disodium is a white to off-white color powder, has the chemical name N-[4-[2-(2-amino-4,7-dihydro-4-oxo-1H-pyrrolo [2,3-d] pyrimidin-5-yl)ethyl]benzoyl]-L-glutamic acid disodium hemi pentahydrate with a molecular formula of C20H19N5Na2O6•2.5H2O and a molecular weight of 516.37. The structural formula is as follows:

Pemetrexed for injection, USP is a sterile white to either light-yellow or green-yellow lyophilized solid or powder in single-dose vials to be reconstituted for intravenous infusion. Each 100 mg vial of pemetrexed for injection, USP contains 100 mg pemetrexed (equivalent to 120.8 mg pemetrexed disodium hemipentahydrate) and 106 mg mannitol. Each 500 mg vial of pemetrexed for injection, USP contains 500 mg pemetrexed (equivalent to 604.1 mg pemetrexed disodium hemipentahydrate) and 500 mg mannitol. Hydrochloric acid and/or sodium hydroxide may have been added to adjust pH.
Households randomly selected for RFR + HIKA will consent to one adolescent (age 10-14 years) to participate in RFR, a youth led animal husbandry economic empowerment intervention, where each youth is provided training and mentorship on raising rabbits. Once the adolescent builds the rabbit cage, the adolescent receives a loan of 2 rabbits to raise and breed, once the rabbit produces offspring, the adolescent repays the rabbit loan with 2 rabbits, one to repay the loan and one to repay the interest on the loan. The original rabbits and the remaining offspring are then for the adolescents to continue to raise, breed, sell, or eat with mentorship from the RFR team and other family members. Parents (mother and father) will consent to complete a 22 week couple's curriculum to increase gender equality (e.g. shared decision making, improved communication and reduced partner violence). The curriculum is delivered for 3 hours weekly by trained facilitators with 12 couples per group.
BACKGROUND/AIM: Esophagectomy for esophageal carcinoma (EC) is known to lead to deterioration of respiratory function (RF) due to thoracotomy and mediastinal lymph node dissection. This study aimed to evaluate the impact of transmediastinal esophagectomy (TME) on pulmonary function.
PATIENTS AND METHODS: We retrospectively analyzed the data of 102 patients with EC who underwent transthoracic esophagectomy (TTE) or TME and underwent RF tests within three months postoperatively at Kyoto Prefectural University of Medicine between 2014 and 2022. Perioperative pulmonary functions were evaluated based on vital capacity (VC) and forced expiratory volume in one second (FEV1.0).
RESULTS: Among 102 patients undergoing esophagectomy, 12 (11.8%) patients were included in the TTE group, and the remaining 90 (88.2%) patients were included in the TME group. Neoadjuvant treatments were significantly more common in the TTE group (p=0.011), with more advanced tumor stages (p=0.017). The TME group had significantly lower estimated blood loss (p=0.015). RF after esophagectomy showed a decrease in VC, and VC of predicted (%VC). The decrease rate in VC, %VC, and FEV1.0 was significantly greater in the TTE group than in the TME group.
CONCLUSION: TME is a surgical procedure with a less severe postoperative decline in RF than TTE.
A process for making a deodorized edible oil or fat having a low level of bound MCPD (monochloro propanediol esters) and/or low level of bound 3-MCPD is described. The process comprises a step of stripping the vegetable oil or fat with an inert gas. The inert gas can be nitrogen. A deodorized vegetable oil or fat and a food product made there from are described. The food product can be an infant formula. It exhibits low levels of bound MCPD and/or low level of bound 3-MCPD. In one embodiment the oil or fat has a reduced level of free fatty acid as well as a limpid aspect and no off-flavors.